Compare CGEM & PRAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CGEM | PRAA |
|---|---|---|
| Founded | 2016 | 1996 |
| Country | United States | United States |
| Employees | N/A | 170 |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 780.4M | 639.1M |
| IPO Year | 2020 | 2002 |
| Metric | CGEM | PRAA |
|---|---|---|
| Price | $14.87 | $18.36 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 3 |
| Target Price | ★ $29.89 | $24.50 |
| AVG Volume (30 Days) | ★ 780.3K | 672.4K |
| Earning Date | 05-29-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,201,837,000.00 |
| Revenue This Year | N/A | $2.01 |
| Revenue Next Year | N/A | $2.53 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 7.83 |
| 52 Week Low | $5.68 | $10.25 |
| 52 Week High | $16.74 | $22.01 |
| Indicator | CGEM | PRAA |
|---|---|---|
| Relative Strength Index (RSI) | 57.60 | 72.50 |
| Support Level | $6.65 | $14.57 |
| Resistance Level | $16.74 | $18.57 |
| Average True Range (ATR) | 1.09 | 1.02 |
| MACD | -0.00 | 0.82 |
| Stochastic Oscillator | 58.17 | 91.92 |
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.
PRA Group Inc is a leader in acquiring and collecting nonperforming loans. The company returns capital to banks and other creditors to help expand financial services for consumers in the Americas, Europe, and Australia. It is also engaged in providing fee-based services on class action claims recoveries in the United States. The company's portfolio segments include; Core, which is engaged in purchasing and collecting nonperforming loans, which the originators have not chosen not to pursue, and the Insolvency segment which is engaged in purchasing and collecting nonperforming loans where the customer is involved in a bankruptcy proceeding.